[Successful treatment of AML by HLA-compatible sibling umbilical cord blood stem cell transplantation--the first case report in China].
To apply umbilical cord blood stem cell transplantation (UCBSCT) to the treatment of hematological malignancies, and to observe the persistent hematopoietic reconstitution, graft-versus-host disease (GVHD) and transplantation-related complications. An 11-year-old patient with acute myeloid leukemia in complete remission (CR) received UCBSCT from a HLA-compatible sibling. The conditioning regimen was BU/CY (busulfan 4 mg.kg-1.d-1 x 4, cyclophosphamide 60 mg.kg-1.d-1 x 2). CsA was given for prophylaxis of acute GVHD. The patient received 0.35 x 10(8) nucleated cells/kg, including 1.82 x 10(4) CFU-GM/kg and 2.04 x 10(5) CD34+ cells/kg. The recipient showed hematopoietic reconstitution on day 14 post-transplantation; ANC > 1.0 x 10(9)/L on day 21; DNA fingerprinting showed engraftment on day 60, the blood type of the patient changed from O group to B group. In the follow-up of 330 days, the patient was in good condition without acute or chronic GVHD. It is the first case reported in China that have succeeded in the treatment of acute myeloid leukemia by allogeneic UCBSCT.